ProQR Therapeutics N.V.
NASDAQ:PRQRBiotechnology
+$0.21 today
- Market cap
- $155.23M
- Beta
- 0.06
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.43
Volume 0.88M
Average 0.62M
PRQR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ProQR Therapeutics N.V.NASDAQ: PRQR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of €13.6M (cash outflow) rose 35.0% year over year, behind the +51.2% change in trailing-twelve-month net income. Sequentially, it rose 53.9% from the prior quarter. Over 3 fiscal years it compounded at -14.2% a year.
Context
- Net income amounted to 265.2% of revenue in FY2025, up 118.4 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -€46.65M (+15.1%) for the fiscal year ending Dec 2026, a slowdown from the +45.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -€13.6M+53.9% QoQ
- Last fiscal yearDec 2025
- -€40.52M+45.9% YoY
- LTMMar 2026
- -€45.62M+51.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +35.0% | +2.8% | -32.1 pp |
| 1 year | +45.9% | +15.1% | -30.8 pp |
| 3-year CAGR | -14.2% | +17.0% | +31.2 pp |
| 5-year CAGR | -9.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
EUR · from the cash flow
- Latest · FY2025
- (40.52M) EUR
- Year-over-year change
- -45.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (40.52M) | -45.9% |
| FY2024 | 2024-12-31 | (27.76M) | -0.1% |
| FY2023 | 2023-12-31 | (27.74M) | +56.8% |
| FY2022 | 2022-12-31 | (64.2M) | -5.6% |
| FY2021 | 2021-12-31 | (60.8M) | — |
Net Income vs competitors
How PRQR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +51.2% is the 3rd highest of 11, against a peer median of +14.0%.
- Net income amounts to 339.4% of revenue for PRQR, versus a peer median of 749.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B USD | +146477.0% | +53.5% | — | |
| LTM Mar 2026 | $239.55M USD | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $173.76M USD | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $166.12M USD | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $108.95M USD | -56.6% | -10.1% | 281.6% | |
| LTM Mar 2026 | $78.67M USD | +15.4% | — | 173.5% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M USD | +24.7% | +35.9% | — |
| FY2025 | A$61.43M AUD | +43.8% | +24.0% | 1218.0% | |
| LTM Mar 2026 | $51.99M USD | +12.6% | +8.9% | — | |
| LTM Mar 2026 | €45.62M EUR | +51.2% | -14.2% | 339.4% | |
| LTM Mar 2026 | $35.71M USD | -24.3% | -0.3% | 7142.0% | |
| Peer median (excluding PRQR) | — | +14.0% | +11.9% | 749.8% | |
Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (60.8M) | (64.2M) | (27.74M) | (27.76M) | (40.52M) |
| Depreciation & Amortization | 2.33M | 2.52M | 2.51M | 2.76M | 2.6M |
| Deferred Income Tax | 117K | 96K | (78K) | (197K) | 0 |
| Stock-Based Compensation | 6.22M | 2.87M | 3.11M | 2.54M | 0 |
| Change in Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 25.01M | (4.99M) | 48.96M | (13.26M) | (16.73M) |
| Other Non-Cash Items | 1.11M | (4.8M) | (5.21M) | (474K) | 3.94M |
| Operating Cash Flow | (26.01M) | (68.51M) | 21.55M | (36.39M) | (50.71M) |
| Capital Expenditures | (484K) | (708K) | (1.37M) | (1.42M) | (979.75K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (17M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 17M | 0 |
| Other Investing Activities | 59K | 6K | 5.65M | (2.66M) | 0 |
| Investing Cash Flow | (425K) | (702K) | 4.28M | (4.07M) | (979.74K) |
| Debt Repayment | 26.84M | (45.05M) | (2.63M) | (1.58M) | (1.91M) |
| Common Stock Issued | 108.48M | 14.12M | 0 | 71.64M | 66.28K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | 34K | 354K | 223K | 75.19K |
| Financing Cash Flow | 136.83M | (30.89M) | (2.28M) | 70.28M | (1.76M) |
| Effect of Forex Changes | 1.29M | 7.35M | 599K | 673K | 14.15M |
| Net Change in Cash | 111.69M | (92.75M) | 24.15M | 30.48M | (39.3M) |
| Free Cash Flow | (26.5M) | (69.22M) | 20.18M | (37.81M) | (51.69M) |
ProQR Therapeutics N.V.
NASDAQ:PRQR
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.